Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due to increase in exercise dyspnea and decrease...
Saved in:
| Main Authors: | E. A. Rezukhina, O. V. Rodnenkov, T. V. Martynyuk |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2021-09-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01) -
CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2019-12-01) -
Assessment of the effectiveness of PAH-specific therapy, including selexipag, in patients with idiopathic pulmonary hypertension according to a comprehensive examination using Raman spectroscopy
by: E. S. Allakhverdiev, et al.
Published: (2023-11-01) -
Possibility of evaluation of oxygen transport function in PAH patients on effective selexipag-based therapy
by: E. S. Allakhverdiev, et al.
Published: (2023-10-01) -
New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01)